BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16421727)

  • 1. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopathologic findings in chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Semin Oncol; 2005 Aug; 32(4):380-94. PubMed ID: 16202684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method.
    Kreft A; Weiss M; Wiese B; Choritz H; Buhr T; Büsche G; Georgii A
    Ann Hematol; 2003 Oct; 82(10):605-11. PubMed ID: 14564478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The development of myelofibrosis in prefibrotic cIMF. An investigation of the progression by sequential bone marrow biopsies in 38 patients].
    Buhr T; Länger F; Kreft A; Büsche G; Choritz H; Kreipe H
    Pathologe; 2002 Nov; 23(6):433-7. PubMed ID: 12436296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
    Buhr T; Büsche G; Choritz H; Länger F; Kreipe H
    Am J Clin Pathol; 2003 Jan; 119(1):152-8. PubMed ID: 12520711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prefibrotic chronic idiopathic myelofibrosis--a diagnostic enigma?
    Thiele J; Kvasnicka HM
    Acta Haematol; 2004; 111(3):155-9. PubMed ID: 15034237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of 161 chronic idiopathic myelofibrosis patients for clinicopathological staging].
    Liu AN; Chen HS; Liu EB; Fang LH; Yang QY; Qian LS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):178-82. PubMed ID: 16792920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Zankovich R; Diehl V
    Am J Hematol; 2002 Aug; 70(4):283-91. PubMed ID: 12210809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up.
    Thiele J; Kvasnicka HM; Zerhusen G; Vardiman J; Diehl V; Luebbert M; Schmitt-Graeff A
    Ann Hematol; 2004 Aug; 83(8):513-21. PubMed ID: 15173958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre-staining processing of bone marrow biopsies.
    Buesche G; Georgii A; Kreipe HH
    Histopathology; 2006 Jan; 48(2):133-48. PubMed ID: 16405662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia.
    Buesche G; Georgii A; Duensing A; Schmeil A; Schlue J; Kreipe HH
    Hum Pathol; 2003 Apr; 34(4):391-401. PubMed ID: 12733122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
    Thiele J; Kvasnicka HM
    Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
    Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
    Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grading of marrow fibrosis in chronic myeloid leukemia--a comprehensive approach.
    Rao S; Sen R; Singh S; Ghalaut PS; Arora BB
    Indian J Pathol Microbiol; 2005 Jul; 48(3):341-4. PubMed ID: 16761746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
    Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of bone marrow reticulin fibres in idiopathic myelofibrosis: evaluation of clinicopathological parameters in a scoring system.
    Iványi JL; Mahunka M; Papp A; Kiss A; Telek B
    Haematologia (Budap); 1994; 26(2):75-86. PubMed ID: 7890265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.